-
Je něco špatně v tomto záznamu ?
Association between duration of smoking abstinence before non-small-cell lung cancer diagnosis and survival: a retrospective, pooled analysis of cohort studies
AF. Fares, Y. Li, M. Jiang, MC. Brown, ACL. Lam, R. Aggarwal, S. Schmid, NB. Leighl, FA. Shepherd, Z. Wang, N. Diao, AS. Wenzlaff, J. Xie, T. Kohno, NE. Caporaso, C. Harris, H. Ma, MJ. Barnett, LF. Leal, G. Fernandez-Tardon, M. Pérez-Ríos, MPA....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem, Research Support, N.I.H., Extramural
Grantová podpora
HHSN268201600018C
NHLBI NIH HHS - United States
P30 CA076292
NCI NIH HHS - United States
HHSN268201600003C
NHLBI NIH HHS - United States
HHSN268201600004C
NHLBI NIH HHS - United States
HHSN268201600001C
NHLBI NIH HHS - United States
U01 CA209414
NCI NIH HHS - United States
UM1 CA167462
NCI NIH HHS - United States
U01 CA063673
NCI NIH HHS - United States
HHSN268201600002C
NHLBI NIH HHS - United States
U01 CA167462
NCI NIH HHS - United States
U19 CA203654
NCI NIH HHS - United States
- MeSH
- kohortové studie MeSH
- kouření epidemiologie MeSH
- lidé MeSH
- nádory plic * diagnóza MeSH
- nemalobuněčný karcinom plic * diagnóza MeSH
- retrospektivní studie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
BACKGROUND: The association between duration of smoking abstinence before non-small-cell lung cancer (NSCLC) diagnosis and subsequent survival can influence public health messaging delivered in lung-cancer screening. We aimed to assess whether the duration of smoking abstinence before diagnosis of NSCLC is associated with improved survival. METHODS: In this retrospective, pooled analysis of cohort studies, we used 26 cohorts participating in Clinical Outcomes Studies of the International Lung Cancer Consortium (COS-ILCCO) at 23 hospitals. 16 (62%) were from North America, six (23%) were from Europe, three (12%) were from Asia, and one (4%) was from South America. Patients enrolled were diagnosed between June 1, 1983, and Dec 31, 2019. Eligible patients had smoking data before NSCLC diagnosis, epidemiological data at diagnosis (obtained largely from patient questionnaires), and clinical information (retrieved from medical records). Kaplan-Meier curves and multivariable Cox models (ie, adjusted hazard ratios [aHRs]) were generated with individual, harmonised patient data from the consortium database. We estimated overall survival for all causes, measured in years from diagnosis date until the date of the last follow-up or death due to any cause and NSCLC-specific survival. FINDINGS: Of 42 087 patients with NSCLC in the COS-ILCCO database, 21 893 (52·0%) of whom were male and 20 194 (48·0%) of whom were female, we excluded 4474 (10·6%) with missing data. Compared with current smokers (15 036 [40·0%] of 37 613), patients with 1-3 years of smoking abstinence before NSCLC diagnosis (2890 [7·7%]) had an overall survival aHR of 0·92 (95% CI 0·87-0·97), patients with 3-5 years of smoking abstinence (1114 [3·0%]) had an overall survival aHR of 0·90 (0·83-0·97), and patients with more than 5 years of smoking abstinence (10 841 [28·8%]) had an overall survival aHR of 0·90 (0·87-0·93). Improved NSCLC-specific survival was observed in 4301 (44%) of 9727 patients who had quit cigarette smoking and was significant at abstinence durations of more than 5 years (aHR 0·87, 95% CI 0·81-0·93). Results were consistent across age, sex, histology, and disease-stage distributions. INTERPRETATION: In this large, pooled analysis of cohort studies across Asia, Europe, North America, and South America, overall survival was improved in patients with NSCLC whose duration of smoking abstinence before diagnosis was as short as 1 year. These findings suggest that quitting smoking can improve overall survival, even if NSCLC is diagnosed at a later lung-cancer screening visit. These findings also support the implementation of public health smoking cessation strategies at any time. FUNDING: The Alan B Brown Chair, The Posluns Family Fund, The Lusi Wong Fund, and the Princess Margaret Cancer Foundation.
American Cancer Society Atlanta GA USA
Barbara Ann Karmanos Cancer Institute Wayne State University Detroit MI USA
Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública Oviedo Spain
Dalla Lana School of Public Health University of Toronto Toronto ON Canada
Dartmouth Hitchcock Medical Center Lebanon NH USA
Department of Clinical Genomics National Cancer Center Research Institute Tokyo Japan
Department of Epidemiology School of Public Health Nanjing Medical University Nanjing China
Department of Health Sciences Research Mayo Clinic Rochester MN USA
Department of Oncology and Metabolism University of Sheffield Sheffield UK
Department of Thoracic Surgery Clinical Center of Serbia Belgrade Serbia
Department of Thoracic Surgery Fudan University Shanghai Cancer Center Shanghai China
Division of Genome Biology National Cancer Center Research Institute Tokyo Japan
Division of Medical Oncology Faculty of Medicine of São José do Rio Preto São Paulo Brazil
Division of Preventive Oncology German Cancer Research Center Heidelberg Germany
Genomic Epidemiology Branch International Agency for Research on Cancer Lyon France
German Cancer Consortium German Cancer Research Center Heidelberg Germany
H Lee Moffitt Cancer Center and Research Institute Tampa FL USA
Harvard T H Chan School of Public Health Harvard University Boston MA USA
Health Research Institute of Asturias Oviedo Spain
Health Research Institute of Santiago de Compostela Santiago de Compostela Spain
Life and Health Sciences Research Institute Medical School University of Minho Braga Portugal
Lunenfeld Tanenbaum Research Institute Sinai Health Systems Toronto ON Canada
M D Anderson Cancer Center University of Texas Houston TX USA
Molecular Oncology Research Center Barretos Cancer Hospital Barretos Brazil
N N Blokhin National Medical Research Centre of Oncology Moscow Russia
National Cancer Institute National Institutes of Health Bethesda MD USA
National Center for Tumor Diseases German Cancer Research Center Heidelberg Germany
National Institute of Public Health Bucharest Romania
Network of Aging Research Heidelberg University Heidelberg Germany
Nofer Institute of Occupational Medicine Łódź Poland
Program in Epidemiology Cancer Prevention Program Fred Hutchinson Cancer Center Seattle WA USA
Public Health Sciences Biostatistics Program Fred Hutchinson Cancer Center Seattle WA USA
Universitätsklinik für Medizinische Onkologie Inselspital Bern Bern Switzerland
University of Hawai'i Cancer Centre University of Hawai'i Honolulu HI USA
Weston Park Cancer Centre Sheffield Teaching Hospital Foundation Trust Sheffield UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23016310
- 003
- CZ-PrNML
- 005
- 20231026110034.0
- 007
- ta
- 008
- 231013s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S2468-2667(23)00131-7 $2 doi
- 035 __
- $a (PubMed)37633678
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Fares, Aline F $u Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada; Division of Medical Oncology, Faculty of Medicine of São José do Rio Preto, São Paulo, Brazil
- 245 10
- $a Association between duration of smoking abstinence before non-small-cell lung cancer diagnosis and survival: a retrospective, pooled analysis of cohort studies / $c AF. Fares, Y. Li, M. Jiang, MC. Brown, ACL. Lam, R. Aggarwal, S. Schmid, NB. Leighl, FA. Shepherd, Z. Wang, N. Diao, AS. Wenzlaff, J. Xie, T. Kohno, NE. Caporaso, C. Harris, H. Ma, MJ. Barnett, LF. Leal, G. Fernandez-Tardon, M. Pérez-Ríos, MPA. Davies, F. Taylor, B. Schöttker, P. Brennan, D. Zaridze, I. Holcatova, J. Lissowska, B. Świątkowska, D. Mates, M. Savic, H. Brenner, A. Andrew, A. Cox, JK. Field, A. Ruano-Ravina, SS. Shete, A. Tardon, Y. Wang, L. Le Marchand, RM. Reis, MB. Schabath, C. Chen, H. Shen, BM. Ryan, MT. Landi, K. Shiraishi, J. Zhang, AG. Schwartz, MS. Tsao, DC. Christiani, P. Yang, RJ. Hung, W. Xu, G. Liu
- 520 9_
- $a BACKGROUND: The association between duration of smoking abstinence before non-small-cell lung cancer (NSCLC) diagnosis and subsequent survival can influence public health messaging delivered in lung-cancer screening. We aimed to assess whether the duration of smoking abstinence before diagnosis of NSCLC is associated with improved survival. METHODS: In this retrospective, pooled analysis of cohort studies, we used 26 cohorts participating in Clinical Outcomes Studies of the International Lung Cancer Consortium (COS-ILCCO) at 23 hospitals. 16 (62%) were from North America, six (23%) were from Europe, three (12%) were from Asia, and one (4%) was from South America. Patients enrolled were diagnosed between June 1, 1983, and Dec 31, 2019. Eligible patients had smoking data before NSCLC diagnosis, epidemiological data at diagnosis (obtained largely from patient questionnaires), and clinical information (retrieved from medical records). Kaplan-Meier curves and multivariable Cox models (ie, adjusted hazard ratios [aHRs]) were generated with individual, harmonised patient data from the consortium database. We estimated overall survival for all causes, measured in years from diagnosis date until the date of the last follow-up or death due to any cause and NSCLC-specific survival. FINDINGS: Of 42 087 patients with NSCLC in the COS-ILCCO database, 21 893 (52·0%) of whom were male and 20 194 (48·0%) of whom were female, we excluded 4474 (10·6%) with missing data. Compared with current smokers (15 036 [40·0%] of 37 613), patients with 1-3 years of smoking abstinence before NSCLC diagnosis (2890 [7·7%]) had an overall survival aHR of 0·92 (95% CI 0·87-0·97), patients with 3-5 years of smoking abstinence (1114 [3·0%]) had an overall survival aHR of 0·90 (0·83-0·97), and patients with more than 5 years of smoking abstinence (10 841 [28·8%]) had an overall survival aHR of 0·90 (0·87-0·93). Improved NSCLC-specific survival was observed in 4301 (44%) of 9727 patients who had quit cigarette smoking and was significant at abstinence durations of more than 5 years (aHR 0·87, 95% CI 0·81-0·93). Results were consistent across age, sex, histology, and disease-stage distributions. INTERPRETATION: In this large, pooled analysis of cohort studies across Asia, Europe, North America, and South America, overall survival was improved in patients with NSCLC whose duration of smoking abstinence before diagnosis was as short as 1 year. These findings suggest that quitting smoking can improve overall survival, even if NSCLC is diagnosed at a later lung-cancer screening visit. These findings also support the implementation of public health smoking cessation strategies at any time. FUNDING: The Alan B Brown Chair, The Posluns Family Fund, The Lusi Wong Fund, and the Princess Margaret Cancer Foundation.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a nemalobuněčný karcinom plic $x diagnóza $7 D002289
- 650 12
- $a nádory plic $x diagnóza $7 D008175
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a kouření $x epidemiologie $7 D012907
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 700 1_
- $a Li, Yao $u Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
- 700 1_
- $a Jiang, Mei $u Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
- 700 1_
- $a Brown, M Catherine $u Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada
- 700 1_
- $a Lam, Andrew C L $u Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada
- 700 1_
- $a Aggarwal, Reenika $u Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada
- 700 1_
- $a Schmid, Sabine $u Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada; Universitätsklinik für Medizinische Onkologie, Inselspital Bern, Bern, Switzerland
- 700 1_
- $a Leighl, Natasha B $u Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada
- 700 1_
- $a Shepherd, Frances A $u Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada
- 700 1_
- $a Wang, Zhichao $u Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA; Division of Pulmonary and Critical Care Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China
- 700 1_
- $a Diao, Nancy $u Harvard T H Chan School of Public Health, Harvard University, Boston, MA, USA
- 700 1_
- $a Wenzlaff, Angela S $u Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
- 700 1_
- $a Xie, Juntao $u Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
- 700 1_
- $a Kohno, Takashi $u Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan
- 700 1_
- $a Caporaso, Neil E $u National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
- 700 1_
- $a Harris, Curtis $u Laboratory of Human Carcinogenesis, Centre for Cancer Research, National Institutes of Health, Bethesda, MD, USA
- 700 1_
- $a Ma, Hongxia $u Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China
- 700 1_
- $a Barnett, Matthew J $u Public Health Sciences, Biostatistics Program, Fred Hutchinson Cancer Center, Seattle, WA, USA
- 700 1_
- $a Leal, Leticia Ferro $u Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
- 700 1_
- $a Fernandez-Tardon, G $u University Institute of Oncology of Asturias-Cajastur Social Programme, University of Oviedo, Oviedo, Spain; Health Research Institute of Asturias, Oviedo, Spain; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública, Oviedo, Spain
- 700 1_
- $a Pérez-Ríos, Mónica $u Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain
- 700 1_
- $a Davies, Michael P A $u Roy Castle Lung Cancer Research Programme, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK
- 700 1_
- $a Taylor, Fiona $u Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK; Weston Park Cancer Centre, Sheffield Teaching Hospital Foundation Trust, Sheffield, UK
- 700 1_
- $a Schöttker, Ben $u Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany; Network of Aging Research, Heidelberg University, Heidelberg, Germany
- 700 1_
- $a Brennan, Paul $u Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France
- 700 1_
- $a Zaridze, David $u N N Blokhin National Medical Research Centre of Oncology, Moscow, Russia
- 700 1_
- $a Holcatova, Ivana $u Institute of Public Health and Preventive Medicine and Department of Oncology, Second Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic
- 700 1_
- $a Lissowska, Jolanta $u Department of Cancer Epidemiology and Prevention, M Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
- 700 1_
- $a Świątkowska, Beata $u Nofer Institute of Occupational Medicine, Łódź, Poland
- 700 1_
- $a Mates, Dana $u National Institute of Public Health, Bucharest, Romania
- 700 1_
- $a Savic, Milan $u Department of Thoracic Surgery, Clinical Center of Serbia, Belgrade, Serbia
- 700 1_
- $a Brenner, Hermann $u Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany; Division of Preventive Oncology, German Cancer Research Center, Heidelberg, Germany; National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany; German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany
- 700 1_
- $a Andrew, Angeline $u Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
- 700 1_
- $a Cox, Angela $u Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
- 700 1_
- $a Field, John K $u Roy Castle Lung Cancer Research Programme, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK
- 700 1_
- $a Ruano-Ravina, Alberto $u Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain
- 700 1_
- $a Shete, Sanjay S $u M D Anderson Cancer Center, University of Texas, Houston, TX, USA
- 700 1_
- $a Tardon, Adonina $u University Institute of Oncology of Asturias-Cajastur Social Programme, University of Oviedo, Oviedo, Spain; Health Research Institute of Asturias, Oviedo, Spain; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública, Oviedo, Spain
- 700 1_
- $a Wang, Ying $u American Cancer Society, Atlanta, GA, USA
- 700 1_
- $a Le Marchand, Loic $u University of Hawai'i Cancer Centre, University of Hawai'i, Honolulu, HI, USA
- 700 1_
- $a Reis, Rui Manuel $u Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil; Life and Health Sciences Research Institute, Medical School, University of Minho, Braga, Portugal; Life and Health Sciences Research Institute-Biomaterials, Biodegradables and Biomimetics Research Group Associate Laboratory, Braga, Portugal
- 700 1_
- $a Schabath, Matthew B $u H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
- 700 1_
- $a Chen, Chu $u Program in Epidemiology, Cancer Prevention Program, Fred Hutchinson Cancer Center, Seattle, WA, USA
- 700 1_
- $a Shen, Hongbing $u Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China
- 700 1_
- $a Ryan, Brid M $u Laboratory of Human Carcinogenesis, Centre for Cancer Research, National Institutes of Health, Bethesda, MD, USA
- 700 1_
- $a Landi, Maria Teresa $u National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
- 700 1_
- $a Shiraishi, Kouya $u Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan; Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan
- 700 1_
- $a Zhang, Jie $u Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
- 700 1_
- $a Schwartz, Ann G $u Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
- 700 1_
- $a Tsao, Ming S $u Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada
- 700 1_
- $a Christiani, David C $u Harvard T H Chan School of Public Health, Harvard University, Boston, MA, USA
- 700 1_
- $a Yang, Ping $u Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
- 700 1_
- $a Hung, Rayjean J $u Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; Lunenfeld-Tanenbaum Research Institute, Sinai Health Systems, Toronto, ON, Canada
- 700 1_
- $a Xu, Wei $u Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. Electronic address: wei.xu@uhnres.utoronto.ca
- 700 1_
- $a Liu, Geoffrey $u Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
- 773 0_
- $w MED00198803 $t The Lancet. Public health $x 2468-2667 $g Roč. 8, č. 9 (2023), s. e691-e700
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37633678 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20231026110028 $b ABA008
- 999 __
- $a ok $b bmc $g 2000058 $s 1202672
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 8 $c 9 $d e691-e700 $e - $i 2468-2667 $m The Lancet. Public health $n Lancet Public Health $x MED00198803
- GRA __
- $a HHSN268201600018C $p NHLBI NIH HHS $2 United States
- GRA __
- $a P30 CA076292 $p NCI NIH HHS $2 United States
- GRA __
- $a HHSN268201600003C $p NHLBI NIH HHS $2 United States
- GRA __
- $a HHSN268201600004C $p NHLBI NIH HHS $2 United States
- GRA __
- $a HHSN268201600001C $p NHLBI NIH HHS $2 United States
- GRA __
- $a U01 CA209414 $p NCI NIH HHS $2 United States
- GRA __
- $a UM1 CA167462 $p NCI NIH HHS $2 United States
- GRA __
- $a U01 CA063673 $p NCI NIH HHS $2 United States
- GRA __
- $a HHSN268201600002C $p NHLBI NIH HHS $2 United States
- GRA __
- $a U01 CA167462 $p NCI NIH HHS $2 United States
- GRA __
- $a U19 CA203654 $p NCI NIH HHS $2 United States
- LZP __
- $a Pubmed-20231013
